Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-lactamase TEM is a plasmid-mediated class A serine beta-lactamase enzyme primarily found in Gram-negative bacteria, such as Escherichia coli and Klebsiella pneumoniae. It plays a critical role in bacterial resistance by catalyzing the hydrolysis of the four-membered beta-lactam ring in penicillins and early-generation cephalosporins, rendering these antibiotics inactive. Over time, numerous mutations in the blaTEM gene have led to the emergence of extended-spectrum beta-lactamases (ESBLs) and inhibitor-resistant TEM (IRT) variants, which significantly expand the enzyme's substrate profile to include third-generation cephalosporins and monobactams.
To combat this resistance mechanism, beta-lactamase inhibitors such as clavulanic acid, tazobactam, and avibactam are co-administered with beta-lactam antibiotics. These inhibitors act either as suicide substrates that covalently and irreversibly bind to the active-site serine residue or as reversible transition-state analogs, thereby protecting the companion antibiotic from degradation and restoring its therapeutic efficacy. However, the rapid evolution of TEM variants remains a major therapeutic challenge, as mutations can alter the active site configuration to evade both traditional and novel inhibitors.
Covalent or reversible inhibition of the active-site serine residue of the beta-lactamase enzyme, preventing the hydrolysis of co-administered beta-lactam antibiotics.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-lactamase TEM (TEM).